<International Circulation>: What improvements have been achieved on the stem cell therapy?
有关干细胞治疗方面有哪些新的进展吗？

Prof. Ferrari：As for the stem cell therapy in cardiology， I believe it is still a matter of studying then. At the present time， we have established that we can safely inject stem cells  into patient with cardiac infarction and heart failure. We’ve proven the short safety， we don’t know yet about the long term safety.  Some of the studies also produce the data on efficacy， but this is not the case in every study. Therefore there is still some doubt on the real efficacy. It is important to understand which type of cell to inject， how many， where， and how， so it is still a matter of experimental study， we have not yet reached the situation that we could use stem cell therapy in every patient.
对于心内科的干细胞治疗，我想它还正处于研究阶段。目前，我们已经能够安全地将干细胞注入到心肌梗死和心衰病人体内。同时证明了这项应用的短期安全性，但还不知道其长期安全性如何。另外，也有一些研究报告了研究结果的有效性，但并不适用于每项研究。因此，对于有效性尚有待考量。重要的是知道注射何种细胞，注射多少，向哪里注射以及如何注射，所以尚有很多实验研究要做。我们目前还不能将其应用到所有病人，因为我们清楚目前的工作进展还没有到这一程度。

<International Circulation>: What hope can be for the AMI therapy in the future about the improvement?
这些研究进步会对未来的AMI治疗带来什么希望？

Prof. Ferrari：There is great hope and potential. Because when the cardiac cells die， they can’t be reproduced， so the idea of injecting stem cells， which will reproduce and will become cardiac cell is fantastic， but we have to be careful， because we are not in the situation of using them so early.
我想这其中很有希望和潜力，因为当心肌细胞死亡后，其很难再生，所以注射干细胞使其不断繁殖并生发为心肌细胞的想法非常巧妙，但是我们对此要极为小心，因为目前还没有到彻底应用的程度。

<International Circulation>:Please introduce the BOOST trial in short words.
请简要介绍一下BUSTA试验

Prof. Ferrari：The BOOST trial is the first controlled trial， showing some benefits in terms of improvement of ejection fraction at 6th months， but no benefits after the 18th month. You don’t treat every patient for benefit only at 6 month， but you should benefit for his whole life!
BUSTA试验是一项对照试验，显示在第6个月的时候会给病人带来收益，但是在18个月后就没有收益了。而你又不可能只在第6个月时给病人带来收益，你应该为病人一生带来收益。